Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.04 | 1.06 | -1.74 |
| EPS, GAAP | 1.00 | 1.02 | 1.02 |
| Consensus Estimate | 1.46 | 1.22 | 19.67 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 5.60 | 4.81 | 16.43 |
| EPS, GAAP | 5.52 | 4.04 | 36.71 |
| Consensus Estimate | 6.58 | 5.33 | 23.42 |
| AMGN | Industry Average | |
| P/E (TTM) | 18.58 | NA |
| P/E (Forward) | 14.44 | NA |
| PEG Ratio | 1.53 | 2.20 |
| Price/Sales | 4.69 | 18.91 |
| Beta | 0.65 | 0.70 |
| 10:20 AM | 3/20/2013 | Model N Shares Rise After IPO |
| 4/5/2013 | 'Guided Missiles' to Treat Cancer (WSJ.com) |
| 4/3/2013 | Drug Firms Expand Powers to Recoup Pay (WSJ.com) |
| 4/3/2013 | Vanguard Reopens Capital Opportunity Fund --- That's a Contrarian Opportunity (Barrons.com) |
| 3/14/2013 | Here's What a Fidelity ETF Might Look Like (Barrons.com) |
| 3/7/2013 | Merck Names New Research Chief; Stock Drops (Barrons.com) |
| 3/7/2013 | Merck Names Former Amgen Executive as Research Chief (WSJ.com) |
| 3/2/2013 | Celgene Drug Results Fall Short of Earlier Trial (WSJ.com) |
| 3/1/2013 | Daily ETF Folly: Why There Is No True Biotech Representation in ETFs (24/7 Wall St) |
